價(jià)格 | ¥238 | ¥556 | ¥792 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 AT7867 | 英文名稱:AT7867 |
CAS:857531-00-1 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.63% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T6304 |
名稱 | AT7867 |
描述 | AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family. |
細(xì)胞實(shí)驗(yàn) | Cells are plated in 96-well microplates at 5 × 103 per well in medium supplemented with 10% fetal bovine serum and grown for 24 hours before treatment with AT7867. AT7867 or vehicle control is added to the cells for 72 hours. Following this, Alamar Blue solution is added. The IC50 value for AT7868 is calculated in GraphPad Prism using nonlinear regression analysis and a sigmoidal dose-response (variable slope) equation.(Only for Reference) |
激酶實(shí)驗(yàn) | In vitro kinase assays : Kinase assays for Akt2, PKA, p70S6K, and CDK2/cyclin A are all carried out in a radiometric filter binding format. Assay reactions are set up in the presence of AT7867. For Akt2, the Akt2 enzyme and 25 μM Aktide-2T peptide (HARKRERTYSFGHHA) are incubated in 20 mM MOPS (pH 7.2), 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, 10 μg/mL bovine serum albumin, and 30 μM ATP (1.16 Ci/mmol) for 4 hours. For PKA, the PKA enzyme and 50 μMpeptide (GRTGRRNSI) are incubated in 2 mM MOPS (pH 7.2), 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM orthovanadate, 1 mM DTT, and 40 μM ATP (0.88 Ci/mmol) for 20 minutes. For p70S6K, the p70S6K enzyme and 25 μMpeptide substrate (AKRRRLSSLRA) are incubated in 10 mM MOPS (pH 7), 0.2 mM EDTA, 1 mM MgCl2, 0.01% β-mercaptoethanol, 0.1 mg/mL bovine serum albumin, 0.001% Brij-35, 0.5% glycerol, and 15 μM ATP (2.3 Ci/mmol) for 60 min. For CDK2, the CDK2/cyclin A enzyme and 0.12 μg/mL histone H1 are incubated in 20 mM MOPS (pH 7.2), 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, 0.1 mg/mL bovine serum albumin, and 45 μM ATP (0.78 Ci/mmol) for 4 hours. Assay reactions are stopped by adding an excess of orthophosphoric acid, and the stopped reaction mixture is then transferred to Millipore MAPH filter plates and filtered. The plates are then washed, scintillant is added, and radioactivity is measured by scintillation counting on a Packard TopCount. IC50 values are calculated from replicate curves using GraphPad Prism software. Akt1 and Akt3 enzyme assays are carried out. |
體外活性 | AT7867不僅抑制與AGC激酶結(jié)構(gòu)相關(guān)的p70S6K和PKA,其IC50分別為20 nM和85 nM,而且對(duì)Akt2顯示出Ki為18 nM的ATP競(jìng)爭(zhēng)性活性。在帶有PTEN或PIK3CA突變的細(xì)胞系中,AT7867展現(xiàn)出抗增殖效果,并且在MES-SA、MDA-MB-468、MCF-7、HCT116和HT29細(xì)胞系中顯示出極大的潛力,其IC50分別為0.94 μM、2.26 μM、1.86 μM、1.76 μM和3.04 μM。AT7867還能抑制U87 mg、PC-3和DU145細(xì)胞的生長(zhǎng),其IC50分別為8.22 μM、10.37 μM和11.86 μM。通過(guò)抑制GSK-3β的磷酸化,AT7867抑制人類腫瘤細(xì)胞中的Akt活性,IC50為2-4 μM。此外,AT7867還誘導(dǎo)U87 mg細(xì)胞中Akt直接底物包括促凋亡轉(zhuǎn)錄因子FKHR (FoxO1a)、FKHRL1 (FoxO3a)以及下游目標(biāo)S6RP的磷酸化。[1] |
體內(nèi)活性 | AT7867在小鼠中經(jīng)口服途徑展現(xiàn)了44%的生物利用度。通過(guò)20 mg/kg的腹腔注射或90 mg/kg的口服給藥,AT7867能夠在MES-SA異種移植瘤中增加裂解的PARP水平。在MES-SA異種移植瘤或U87 mg異種移植瘤中,AT7867顯著抑制了腫瘤的生長(zhǎng),其T/C分別為0.37和0.51。[1] |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 63 mg/mL (186.5 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 5 mg/mL (14.79 mM) |
關(guān)鍵字 | Akt | PKA | Inhibitor | Ribosomal S6 Kinase (RSK) | inhibit | AT7867 | AT 7867 | S6K | Protein kinase A | Protein kinase B | PKB | AT-7867 |
相關(guān)產(chǎn)品 | JAK1/2/3 Inhibitor 1 | Honokiol | AKT Kinase Inhibitor | Sodium salicylate | Artemisinin | Acefylline | Staurosporine | 8-Bromo-cAMP sodium salt | 2,3-Butanediol | Oridonin | Ro-3306 | Ethyl gallate |
相關(guān)庫(kù) | 抑制劑庫(kù) | 經(jīng)典已知活性庫(kù) | 抗癌活性化合物庫(kù) | 已知活性化合物庫(kù) | 激酶抑制劑庫(kù) | 抗衰老化合物庫(kù) | NO PAINS 化合物庫(kù) | 谷氨酰胺代謝化合物庫(kù) | 疼痛相關(guān)化合物庫(kù) | 酪氨酸激酶分子庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2024-12-27 | |
詢價(jià) |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
¥272.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 | |
¥1098.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2024-10-31 | |
詢價(jià) |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
¥2637 |
上海高創(chuàng)化學(xué)科技有限公司
|
2020-01-17 | ||
¥2637.11 |
Selleck中國(guó)
|
2020-01-13 | ||
詢價(jià) |
-
|
2019-12-20 |